FBLG
FibroBiologics, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$6.18M
P/E Ratio
—
EPS
$-8.40
Beta
1.10
52W High
$22.60
52W Low
$1.03
50-Day MA
$4.12
200-Day MA
$7.54
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About FibroBiologics, Inc. Common Stock
FibroBiologics, Inc. is a leading biotechnology company at the forefront of regenerative medicine, specializing in the innovative application of fibroblast cells to address degenerative diseases and spinal disorders. With a solid intellectual property portfolio, the company is well-positioned in the competitive cellular therapy market, emphasizing clinical innovation and excellence. Through strategic collaborations and active research efforts, FibroBiologics is committed to revolutionizing healthcare and improving patient outcomes with its groundbreaking therapeutic products.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-16.41M |
| Operating Margin | 0.00% |
| Return on Equity | -419.40% |
| Return on Assets | -79.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.85 |
| Price-to-Book | 1.00 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $4.54M |
| Float | $2.93M |
| % Insiders | 14.47% |
| % Institutions | 8.33% |
Analyst Ratings
Consensus ($19.00 target)
1
Strong Buy1
Buy1
HoldData last updated: 4/29/2026